The effect of fexofenadine on pruritus in a mouse model (HR-ADf) of atopic dermatitis

H. Akamatsu, M. Makiura, Naoki Yamamoto, Akiko Yagami, Y. Shimizu, K. Matsunaga

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Fexofenadine, a histamine H 1 -receptor antagonist, is approved for the treatment of pruritus associated with atopic dermatitis. The effects of fexofenadine on scratching behaviour, and plasma levels of histamine and eotaxin were assessed in a new model of atopic dermatitis. Mice fed a diet low in M9 2+ and Zn 2+ (special diet S) were compared with mice on a normal diet (N) or diet S plus fexofenadine HCl for weeks 0 - 10 (S + F 0-10 ), 0 - 5 (S + F 0-5 ) or 6 - 10 (S + F 6-10 ) (seven mice per group). Compared with group N, group S mice showed significantly greater scratching frequency, and plasma histamine and eotaxin concentrations; these three variables were significantly lower in group S + F 0-10 than in group S. Scratching frequency increased when fexofenadine was discontinued. Fexofenadine significantly reduced mast cell and eosinophil numbers. Histamine may be important in the pathological changes seen in this model of atopic dermatitis, suggesting that it might aid future development of antihistamines for the treatment of atopic dermatitis.

Original languageEnglish
Pages (from-to)495-504
Number of pages10
JournalJournal of International Medical Research
Volume34
Issue number5
DOIs
Publication statusPublished - 01-01-2006

Fingerprint

fexofenadine
Atopic Dermatitis
Pruritus
Nutrition
Histamine
Diet
Plasmas
Histamine Antagonists
Eosinophils
Mast Cells
Cell Count

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

@article{2a33f1efd8304448b03a897089d83ca3,
title = "The effect of fexofenadine on pruritus in a mouse model (HR-ADf) of atopic dermatitis",
abstract = "Fexofenadine, a histamine H 1 -receptor antagonist, is approved for the treatment of pruritus associated with atopic dermatitis. The effects of fexofenadine on scratching behaviour, and plasma levels of histamine and eotaxin were assessed in a new model of atopic dermatitis. Mice fed a diet low in M9 2+ and Zn 2+ (special diet S) were compared with mice on a normal diet (N) or diet S plus fexofenadine HCl for weeks 0 - 10 (S + F 0-10 ), 0 - 5 (S + F 0-5 ) or 6 - 10 (S + F 6-10 ) (seven mice per group). Compared with group N, group S mice showed significantly greater scratching frequency, and plasma histamine and eotaxin concentrations; these three variables were significantly lower in group S + F 0-10 than in group S. Scratching frequency increased when fexofenadine was discontinued. Fexofenadine significantly reduced mast cell and eosinophil numbers. Histamine may be important in the pathological changes seen in this model of atopic dermatitis, suggesting that it might aid future development of antihistamines for the treatment of atopic dermatitis.",
author = "H. Akamatsu and M. Makiura and Naoki Yamamoto and Akiko Yagami and Y. Shimizu and K. Matsunaga",
year = "2006",
month = "1",
day = "1",
doi = "10.1177/147323000603400506",
language = "English",
volume = "34",
pages = "495--504",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "5",

}

The effect of fexofenadine on pruritus in a mouse model (HR-ADf) of atopic dermatitis. / Akamatsu, H.; Makiura, M.; Yamamoto, Naoki; Yagami, Akiko; Shimizu, Y.; Matsunaga, K.

In: Journal of International Medical Research, Vol. 34, No. 5, 01.01.2006, p. 495-504.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of fexofenadine on pruritus in a mouse model (HR-ADf) of atopic dermatitis

AU - Akamatsu, H.

AU - Makiura, M.

AU - Yamamoto, Naoki

AU - Yagami, Akiko

AU - Shimizu, Y.

AU - Matsunaga, K.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Fexofenadine, a histamine H 1 -receptor antagonist, is approved for the treatment of pruritus associated with atopic dermatitis. The effects of fexofenadine on scratching behaviour, and plasma levels of histamine and eotaxin were assessed in a new model of atopic dermatitis. Mice fed a diet low in M9 2+ and Zn 2+ (special diet S) were compared with mice on a normal diet (N) or diet S plus fexofenadine HCl for weeks 0 - 10 (S + F 0-10 ), 0 - 5 (S + F 0-5 ) or 6 - 10 (S + F 6-10 ) (seven mice per group). Compared with group N, group S mice showed significantly greater scratching frequency, and plasma histamine and eotaxin concentrations; these three variables were significantly lower in group S + F 0-10 than in group S. Scratching frequency increased when fexofenadine was discontinued. Fexofenadine significantly reduced mast cell and eosinophil numbers. Histamine may be important in the pathological changes seen in this model of atopic dermatitis, suggesting that it might aid future development of antihistamines for the treatment of atopic dermatitis.

AB - Fexofenadine, a histamine H 1 -receptor antagonist, is approved for the treatment of pruritus associated with atopic dermatitis. The effects of fexofenadine on scratching behaviour, and plasma levels of histamine and eotaxin were assessed in a new model of atopic dermatitis. Mice fed a diet low in M9 2+ and Zn 2+ (special diet S) were compared with mice on a normal diet (N) or diet S plus fexofenadine HCl for weeks 0 - 10 (S + F 0-10 ), 0 - 5 (S + F 0-5 ) or 6 - 10 (S + F 6-10 ) (seven mice per group). Compared with group N, group S mice showed significantly greater scratching frequency, and plasma histamine and eotaxin concentrations; these three variables were significantly lower in group S + F 0-10 than in group S. Scratching frequency increased when fexofenadine was discontinued. Fexofenadine significantly reduced mast cell and eosinophil numbers. Histamine may be important in the pathological changes seen in this model of atopic dermatitis, suggesting that it might aid future development of antihistamines for the treatment of atopic dermatitis.

UR - http://www.scopus.com/inward/record.url?scp=33751044561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751044561&partnerID=8YFLogxK

U2 - 10.1177/147323000603400506

DO - 10.1177/147323000603400506

M3 - Article

VL - 34

SP - 495

EP - 504

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 5

ER -